In Europe, salmonellosis remains the second most common foodborne disease1, while hepatitis E virus (HEV) prevalence in humans has increased significantly during recent decades.2 Studies proved that pigs are common hosts of Salmonella and HEV. Hence, pork products classify as a risk factor for these zoonotic diseases. Costs of selected biosecurity measures (11) along the PPC BSM-specific calculations Country-specific values used if available Costs evaluated per sow, slaughter pig or farm conditioned by the BSM Published data, national guidelines, experts Salmonella Hepatitis E Pork production chain Consumer Biosecurity measures BSM-effect considered in QMRA QMRA OUTPUT Output translated to monetary benefits BENEFITS COSTS Economic analysis Cost-benefit analysis conducted for each of the pathogens Disease Output = change in the number of human cases due to selected biosecurity measures along the PPC Pork production chain associated incidences To assess the cost-effectiveness of the considered biosecurity measures Introduction 1 Concept and methods applied 2 Development of an economic model to assess the cost-effectiveness of biosecurity measures to reduce the burden of Salmonella and hepatitis E virus in the pork production chain Bester C.1, Marschik T. 1, Schmoll F. 2, Käsbohrer A. 1,3 1Unit of Veterinary Public Health and Epidemiology, University of Veterinary Medicine Vienna 2 Division for Animal Health, Austrian Agency for Health and Food Safety (AGES) Moedling, Austria 3 Unit Epidemiology, Zoonoses and Antimicrobial Resistance, German Federal Institute for Risk Assessment, Berlin, Germany ►Specific effective BSMs collated within BIOPIGEE will be evaluated in the pathogen-specific quantitative microbial risk assessment models (QMRA), parameterized for selected countries. The output, namely reduced human cases and prevalence in pigs, will be translated into monetary terms. In a cost-benefit analysis, the disease-specific associated costs and costs of BSMs will be evaluated against the monetary benefits of the reduced incidences and prevalence. The calculations are based on country-specific data on disease rates, cost of disease, and cost for the implementation of specific BSMs, as well as information on national pig farming structure and pork production statistics. Cost of illness Pathogen-specific methodology applied Salmonella3* Hepatitis E4,5 Country Cost per human case, 2019 Average across pathogen-specific severity outcomes AT € 980.4 € 408.2 UK € 1,217.2 € 424.3 DE € 959.6 € 414.1 FR € 771.9 € 410.2 Biosecurity measures 3 (1) EFSA, Zoonosis Report, 2020 (4) Anckorn et al., 2020 (2) Adlhoch et al., 2016 (5) Mangen et al., 2014 (3) FCC Consortium, 2010 (6) Pires et al., 2011 This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 773830. * Consideration of an underreporting factor (7.3)1 and a region specific source attribution factor6 Flow of processes Effect Risk BSM-specific risk ratio Reductions of human cases as well as prevalence reduction in pigs and associated monetary benefits will be considered provided sufficient data is available. Disease-associated economic effects play an important role in decision- making processes. Significant economic consequences have been identified as a result of pork-attributable human salmonellosis cases (approximately € 90 million annually in the European Union).3 In contrast, the monetary impact of HEV cases has not yet been determined. ►The present analysis evaluates the cost-effectiveness of specific BSMs proven to reduce the prevalence of Salmonella or HEV at specific stages along the pig production chain (PPC). The following demonstrates the concept behind the analysis. Effective biosecurity measures (BSM) along the production chain can reduce this impact. Therefore, the cost-effectiveness of applicable BSMs must be evaluated to support the establishment of national disease control programmes. The